MDACC Study No:2013-0051 ( NCT No: NCT01981850)
Title:A Phase 2, Open-Label, Prospective Study Of PRM-151 In Subjects
With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF
(post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET
Principal Investigator:Srdan Verstovsek
Treatment Agent:PRM-151
Study Status:Open
Study Description:The goal of this clinical research study is to learn if PRM-151 can help to
control MF. Two (2) different dosing schedules will be compared. The safety
of this drug will also be studied.

PRM-151 is designed to be active at places in the body where there is tissue
damage, which may help to control tissue scarring.

Some participants will also receive ruxolitinib. Ruxolitinib is designed to
block some of the proteins in the blood that may cause MF symptoms.
Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:PRM-151
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Promedior, Incorporated
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults